Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Non-Current Deffered Revenue (2016 - 2025)

Ocular Therapeutix (OCUL) has 12 years of Non-Current Deffered Revenue data on record, last reported at $14.0 million in Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue changed 0.0% year-over-year to $14.0 million; the TTM value through Dec 2025 reached $14.0 million, changed 0.0%, while the annual FY2025 figure was $14.0 million, 0.0% changed from the prior year.
  • Non-Current Deffered Revenue reached $14.0 million in Q4 2025 per OCUL's latest filing, roughly flat from $14.0 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $14.3 million in Q2 2023 and bottomed at $12.0 million in Q1 2021.
  • Average Non-Current Deffered Revenue over 5 years is $13.5 million, with a median of $14.0 million recorded in 2024.
  • Peak YoY movement for Non-Current Deffered Revenue: rose 12.78% in 2022, then fell 1.78% in 2024.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $13.0 million in 2021, then increased by 2.98% to $13.4 million in 2022, then grew by 5.59% to $14.1 million in 2023, then fell by 0.96% to $14.0 million in 2024, then changed by 0.0% to $14.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $14.0 million in Q4 2025, $14.0 million in Q3 2025, and $14.0 million in Q2 2025.